Literature DB >> 8382512

Salvage treatment in male patients with germ cell tumours.

D Josefsen1, S Ous, J Høie, A E Stenwig, S D Fosså.   

Abstract

The outcome of salvage treatment was reviewed in 55 patients relapsing during or after their primary chemotherapy for advanced malignant germ cell tumours. Fifty-two patients had been given cisplatin-based chemotherapy as their primary treatment, whereas three patients had received carboplatin-based chemotherapy. The median time to relapse was 2 months (range: 0-96 months) from discontinuation of the primary treatment. Two patients underwent radical surgery only, and one patient had radiotherapy to a brain metastasis as his only curatively intended salvage treatment. Six patients did not receive any treatment for their recurrent malignancy (refusal, terminal condition) except for purely palliative measures. The disease-free survival for the total group was 27% at 5 years. Complete response to primary treatment lasting for > or = 6 months was the only parameter which significantly predicted a favourable outcome (45% 5 year disease-free survival in 12 eligible patients).

Entities:  

Mesh:

Year:  1993        PMID: 8382512      PMCID: PMC1968255          DOI: 10.1038/bjc.1993.104

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.

Authors:  A Horwich; D P Dearnaley; J Nicholls; G Jay; M Mason; S Harland; M J Peckham; W F Hendry
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

2.  High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors.

Authors:  E R Broun; C R Nichols; G Tricot; P J Loehrer; S D Williams; L H Einhorn
Journal:  Bone Marrow Transplant       Date:  1991-01       Impact factor: 5.483

3.  High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group.

Authors:  G Stoter; D T Sleyfer; W W ten Bokkel Huinink; S B Kaye; W G Jones; A T van Oosterom; C P Vendrik; P Spaander; M de Pauw; R Sylvester
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

4.  The growing teratoma syndrome.

Authors:  S G Basheda; G Gephardt; D P Meeker
Journal:  Chest       Date:  1991-07       Impact factor: 9.410

5.  Management of patients with poor-prognosis nonseminomatous germ cell cancer.

Authors:  S D Fosså; G Saeter; N Aass; S Ous; A E Stenwig; V Blomlie
Journal:  Oncology       Date:  1990       Impact factor: 2.935

6.  Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors.

Authors:  R J Motzer; K Cooper; N L Geller; D G Pfister; S Y Lin; D Bajorin; H I Scher; H Herr; W Fair; M Morse
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

7.  Prognosis in patients with metastatic non-seminomatous testicular cancer.

Authors:  N Aass; S D Fosså; S Ous; A E Stenwig; H H Lien; E Paus; O Kaalhus
Journal:  Radiother Oncol       Date:  1990-04       Impact factor: 6.280

8.  A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.

Authors:  J P Eder; A Elias; T C Shea; S M Schryber; B A Teicher; M Hunt; J Burke; R Siegel; L E Schnipper; E Frei
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

9.  Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989).

Authors:  R J Motzer; N L Geller; C C Tan; H Herr; M Morse; W Fair; J Sheinfeld; P Sogani; P Russo; G J Bosl
Journal:  Cancer       Date:  1991-03-01       Impact factor: 6.860

10.  The changing role of surgery in metastatic non-seminomatous germ cell tumour.

Authors:  J Cassidy; C R Lewis; S B Kaye; D Kirk
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more
  6 in total

Review 1.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

2.  Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer.

Authors:  A Gerl; C Clemm; P Kohl; A Schalhorn; W Wilmanns
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

3.  Salvage therapy of germ cell tumours.

Authors:  A Horwich
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

4.  Prognosis after salvage treatment for unselected male patients with germ cell tumours.

Authors:  A Gerl; C Clemm; N Schmeller; R Hartenstein; R Lamerz; W Wilmanns
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

5.  Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.

Authors:  S D Fosså; S P Stenning; A Gerl; A Horwich; P I Clark; P M Wilkinson; W G Jones; M V Williams; R T Oliver; E S Newlands; G M Mead; M H Cullen; S B Kaye; G J Rustin; P A Cook
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

6.  First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.

Authors:  C Bokemeyer; N Schleucher; B Metzner; M Thomas; O Rick; H-J Schmoll; C Kollmannsberger; I Boehlke; L Kanz; J T Hartmann
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.